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Determinants of neonatal IgE level: parity, maternal age, birth
season and perinatal essential fatty acid status in infants of atopic
mothers
Objective: The hygiene hypothesis suggests that the protective 'siblings effect'
against atopic diseases such as atopic dermatitis, allergic asthma and hay fever is
a result of recurrent infections during early childhood. A recent study and review
have indicated that this protective effect may already arise in utero. Lower n-3
essential fatty acid (EFA) status is associated with increased parity, and EFA
status has also been related to atopy. The present study confirms the negative
association between parity and neonatal immunoglobulin E (IgE) levels and
further unravel the role of perinatal EFA status.
Methodology: In a prospective cohort study in 184 atopic mothers and their
neonates, we simultaneously measured serum total IgE and EFA levels in plasma
phospholipids, both in the mother at 34-36 weeks of gestation and in the
neonate at the age of 1 week. Linear regression analysis was used to estimate
the effect of parity on maternal and neonatal IgE and EFA status, and the
independent effects of parity and EFA status on IgE, controlling for
confounding factors such as maternal age and birth season.
Results: Parity was associated with lower neonatal IgE level (P < 0.01), as well
as with lower docosahexanoic acid (DHA, 22:6n-3) status of the mother
(P = 0.01) but not of the neonate (P > 0.69). In the multivariate analysis,
higher parity, higher maternal IgE, lower maternal age and birth in the first
3 months of the year were independently associated with neonatal IgE level. No
association was detected between maternal or neonatal EFA status and neonatal
IgE.
Conclusions: As neonatal total serum IgE is predictive of later atopy, our results
support the hypothesis that the sibling effect in atopy is already being
programmed in utero. Our data also confirm earlier findings that DHA
status is lower in multiparous women, but this did not confound the relation
between parity and neonatal IgE.
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The prevalence of atopic eczema in the Western world
has increased two- to threefold over the last three
decades (1). Several theories have been put forward to
explain this increase, most of them focusing on early life
events. One example of such theories is the hygiene
hypothesis. This was first postulated by Strachan (2),
who found the prevalence of hay fever and atopic
dermatitis (AD) to be inversely related to the number of
older siblings. Similar associations have been reported
since (1, 3, 4). This effect has been tentatively explained
by the greater chances of cross-infection from older
siblings in large families, which may have an important
protective role in the expression of atopy: the so-called
sibling effect. The age of infection might be crucial, as it
has also been found that the rise of AD in the first year
of life is negatively associated with the number of
children in the household, the so-called sibling-effect (5).
A recent study by Karmaus et al. (6) suggested that cord
blood immunoglobulin E (IgE) levels decrease with
increasing birth order. The literature is ambivalent
about whether cord blood IgE is predictive for the later
development of atopy or not. However, the concentra-
tion of total IgE in umbilical cord blood was found in
several studies to be positively associated with later
development of atopy (7, 8, 36, 37), the sibling effect
may have its origin (at least partly) in utero. If this
hypothesis were correct, neonatal IgE would be expected
to be negatively associated with increasing parity.
Maternal essential fatty acid (EFA) status is also
influenced by parity, and has also been implicated in the
development of atopy. It has long been recognized that
atopic and nonatopic individuals differ with respect to the
proportions of various polyunsaturated fatty acids in
their blood (9, 38, 39). Studies in adults have found
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increased levels of linoleic acid (18:3n-6, LA) and
alpha-linolenic acid (18:3n-3, ALA), and decreased levels
of n-6 and n-3 long chain polyenes (LCPs) in blood,
adipose tissue and human milk of atopic individuals
(10-13). The LCPs, n-6 and n-3 derivatives of LA and
ALA, respectively, are the precursors of inflammatory
mediators such as prostaglandins and leukotrienes and
are embedded in cell membranes, where they play a role
in membrane fluidity and signal transduction. An earlier
study showed that low n-6 LCP levels in cord blood
precede the development of atopy in infants (14), which
might suggest a causal relationship and points to the
importance of neonatal EFA status.
Neonatal EFA status depends on intrauterine EFA
supply. Parity would, however, be expected to increase
the risk of atopic disease if maternal EFA status is
depleted by earlier pregnancies. Increasing parity has
indeed shown to be associated with relative n-3 LCP
depletion, most notably of docosahexanoic acid (DHA)
as a marker of n-3 EFA status; maternal DHA status has
been shown to decrease during a normal pregnancy (15)
and to decrease further with increasing parity (16).
We studied the effect of parity on neonatal total serum
IgE levels and on perinatal DHA status, as well as their
inter-independence, as part of an ongoing study of the
relationship between the development of atopy and
EFAs. We also explored whether DHA or other perinatal
EFAs are an intermediate or confounding factor in the
relationship between parity and neonatal IgE.
Materials and methods
Study design and population
This study was initially designed to determine (1) the relationship in
a 64 infants of breastfed neonates between the mothers' prepartum
EFA status, EFA in breast milk, and the children's EFA status on
the one hand and the development of atopic disease at the age of
1 year on the other; and (2) whether supplementing bottle-fed
neonates with gamma-linolenic acid (GLA, 18:3n-6) from 1 week of
age until 6 months prevents atopic disease at the age of 1 year (118
infants) (34). Formula feeding meant exclusive formula feeding after
1 week of life and exclusive breastfeeding meant no formula at all in
the first 4 weeks of life.
Subjects eligible for the study were atopic pregnant women and
their neonates. They were recruited between October 1997 and April
2000 by midwives and via advertisements in local newspapers in the
provinces of Limburg and Noord-Brabant (the Netherlands). The
atopic status of both parents was assessed using a validated tele-
phone questionnaire. Inclusion criteria for atopic mothers were: a
history of allergic asthma or allergic rhinoconjunctivitis (in relation
to aeroallergen exposure), or a history of AD, and/or a history of
positive allergy test, and/or improvement of asthma or rhinocon-
junctivitis complaints by antihistamine drugs. Noninclusion criteria
were: diabetes treated with medication and/or a prescribed diet,
(pre-)-eclampsia and metabolic diseases.
Neonates were born between December 1997 and May 2000.
Inclusion criteria for the neonates were: gestational age of at least
38 weeks, birth weight > 2500 g and an uncomplicated birth and
neonatal period.
Sampling and laboratory analyses
Blood was collected from the mothers by venepuncture of the median
cubital vein at 34-36 weeks of gestation, and from the infants at the
age of about 1 week (5-8 days) by heel prick. Blood was collected in
EDTA-containing tubes (Becton Dickinson, Orangeburg, SC, USA)
and serum separator tubes (Sherwood-Davis & Geek, St Louis, MO,
USA). The samples were transported on ice/water mixture and,
within 24 h after collection, centrifuged for 10 min (3000 g at 4°C),
and stored at -20°C (serum) or -50°C (plasma) under nitrogen until
analysis. If an insufficient amount of venous blood was acquired from
the mother, finger prick blood was collected on blotting paper for
total serum IgE analysis. Neonatal blood sampling always preceded
the start of the GLA supplementation.
Fatty acids (FAs) in plasma phospholipids were analyzed as
previously described (17). Briefly, lipid extracts were prepared
from plasma samples, and phospholipid (PL) fractions separated
using aminopropyl-bonded phase columns (18). PLs were hydro-
lyzed and FAs transmethylated with boron trifluoride (Sigma,
St Louis, MO, USA) in methanol. The composition of the FA
methyl esters obtained was determined by capillary gas chroma-
tography using a polar capillary column (CPSil 88; Chrompack,
Middelburg, the Netherlands), with helium as the carrier gas. The
amount of each FA was quantified by adding an internal standard
(dinonadecanoyl [19:0]-phosphatidylcholine; Sigma). Results are
reported as weight percentage (wt%) of total FAs, computed as
previously described (15).
Specific IgE tests against a battery of food allergens (Fx5),
aeroallergens (Phadiatop, cut-off point 0.35 kU/l) and a test for
total seruni IgE (detection limit 0.02 kU/l) in the mother were
performed in serum using the Pharmacia Unicap system (Phar-
macia Upjohn, Uppsala, Sweden) as described elsewhere (19).
Total IgE (detection limit 0.15 kU/l) in the neonates was deter-
mined at the Central Laboratory of the blood-transfusion services
in Amsterdam. This was done in eluded blood spot material in a
sandwich assay, according to Aalberse et al. (20), with minor
modifications: a mixture of anti-human IgE monoclonal antibodies
was coupled to Sepharose 4B to catch IgE, and Sepharose-bound
IgE was detected by means of radio-labeled antibodies against
human IgE, raised in sheep.
Statistical analysis
We evaluated three hypotheses: (1) parity influences maternal and
neonatal total serum IgE, (2) parity influences DHA depletion in the
mother during pregnancy and (3) the possible role of DHA as a
confounder or as an intermediate factor in the relationship between
parity and neonatal total serum IgE. In an explorative analysis, we
assessed whether other EFAs were associated with neonatal IgE.
The significant P-value used in the analysis was P < 0.05. If total
serum IgE was nondetectable the value 0.01 was assigned for the
linear regression analyses.
The main outcome variables for the first hypothesis were total
serum IgE levels of mothers at 34-36 weeks of gestation (maternal
IgE) and of neonates at 1 week of age (neonatal IgE). Total serum
IgE was not normally distributed and was therefore transformed to
its natural logarithm (In IgE). Linear regression analysis, as single-
step analysis, was applied to estimate the strength of the associ-
ation between the outcome variables and parity, controlling for
possible confounding factors [maternal age, season of birth,
smoking during pregnancy and, in the case of the neonates, gender,
maternal IgE, atopy of the father and type of feeding (formula or
breast milk)].
The main outcome variables for the second hypothesis were
maternal and neonatal DHA levels. Linear regression analysis, as
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single-step analysis, was applied to estimate the strength of the
association between these outcome variables and parity.
The main outcome variable for the third hypothesis was neo-
natal total serum IgE (In IgE). The possible role of DHA as a
confounder or as an intermediate factor in the relationship
between parity and neonatal total serum IgE was assessed by
applying linear regression analysis to estimate the strength of the
association between the outcome variables and parity, control-
ling for DHA in addition to the other possible confounding
factors.
The explorative analysis assessed whether other EFAs were
associated with neonatal total serum IgE, controlling for other
covariables. We tested for influential outliers by calculating
Cooks distances. Cooks distance < 1 was considered to be
normal. The EFAs included in the analyses were LA (18:2n-3),
GLA (18:3n-6), dihomo-gamma-linolenic acid (DGLA, 20:3n-6),
arachidonic acid (AA, 22:4n-6), adrenic acid (22:4n-6), Osbond
acid (22:5n-6), ALA (18:3n-3), 18:4n-3, eicosapentaenoic acid
(EPA, 20:5n-3) and docosapentanoic acid (DPA, 22:5n-3). To
facilitate the interpretation of the regression coefficients when
comparing the association of each EFA with IgE, we computed
standardized regression coefficients (=regression coeffi-
cient x [SD(x)/SD(y)], where SD(x) is the standard deviation of
the EFA and SD(y) is the standard deviation of In IgE in the
study population) (21).
Statistical analyses were performed by means of the SPSS for
Windows program (version 10.0; SPSS, Inc., Chicago, IL, USA).
Results
Study population
One hundred and eighty-two mothers with their neonates
were included in the study. As shown in Table 1, almost
half of the mothers were primipara (47%), while 37% of
the mothers had had one previous infant, 13% had had
two previous infants and 3% had had three previous
infants. Sixty-four neonates were exclusively breastfed
and 118 neonates were formula-fed in the first week.
Seventy-nine percent of the mothers had a positive
inhalant allergen test (Phadiatop) and 14% had a positive
food allergen test (Fx5) (Table 1).
Total serum IgE
Increasing parity was associated with decreasing total
serum IgE in the neonates (P = 0.006) (Table 2). The
regression coefficient of -0.57 can be interpreted as
follows: with each subsequent child, the neonatal IgE
level increases by a factor exp(-0.57) = 0.57 (95%
confidence interval 0.40-0.85), i.e. the IgE level is almost
halved. There was also a statistically significant effect of
Table 1. Characteristics of mothers and neonates
n
Maternal total serum IgE kU/l,
median (SD)
50-99 kU/l, n
100-199 kU/l, n
>200 kU/l, n
Maternal positive Phadiatoptt, n (%)
Maternal positive Fx5*t n |%)
Smoking in pregnancy by mother, n (%)
Paternal positive history of atopy, n {%)
Age mother at delivery, mean (SD)
Breastfeeding, n (%)
Season of birth neonate
First (January, February, March), n (%)
Second (April, May, June), n (%)
Third (July, August, September), n (%)
Fourth (October, November,
December), n (%)
Boys, n (%)
Infant IgE at 1 week kU/l, median (SD)§
Nondetectable, n
0.15-0.5, n
0.5-18, n
1
85
178 (728)
36
15
34
64 (80)
16 (20)
18(21)
30 (36)
29(4)
28 (33)
20 (24)
17 (20)
34 (40)
14(16)
36 (42)
0.30 (3.9)
34
15
32
Parity, n (%)
2
68
92.5(451)
36
11
21
53 (80)
8(12)
8(12)
26 (38)
32(3)
27 (40)
14 (21)
21 (31)
22 (32)
11 (16)
28 (41)
0.30 (2.9)
24
20
24
>3
29*
55(191)
19
3
7
20 (77)
2(7)
5(17)
10(34)
34(3)
9(31)
6(21)
11(38)
8(28)
4(14)
22 (75)
0.21 (0.5)
14
9
6
Total
182
100(578)
91
29
62
137 (79)
26 (15)
31 (17)
66 (36)
31.35(3.85)
64 (35)
40 (22)
49 (27)
64 (35)
29 (16)
86 (47)
0.30 (3.26)
72
44
62
n, number of participants; SD, standard deviation; Phadiatop, specific inhalant allergy test (positive if >0.35 kU/l); Fx5, food allergy test directed against cow's milk, egg-white,
soy, shell fish, nuts, wheat.
* 24 mothers had parity 3, five had parity 4.
t Number of participants with positive specific test according to total serum IgE level.
t Missing specific IgE in mothers n = 9 (parity 1, n = 5; parity 2, n = 2; parity >3, n = 2).
§ Missing total IgE in infants, n — 4.
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Table 2. IgE as natural logarithm (In) in total serum of mothers at 34-36 weeks of gestation and in neonates at 1 week of age, in relation to parity and other determinants
Mother 34-36 weeks of gestation (n = 182) Neonate at 1 week of age (n = 178*)
Regression coefficient Standard error P-value Regression coefficient Standard error P-value
Parity (1,2, 3, 4)
Age mother at delivery (years)
In IgE mother (In kU/l)
Smoking during pregnancy (0 = no, 1 = yes)
Season of birth
First (January, February, March)
Second (April, May, June)
Third (July, August, September)
Fourth (October, November, December)
Atopy father (0 = no, 1 = yes)
Gender (1 = boy, 2 = girl)
Type of feeding (0 = formula, 1 = breast milk)
-0.23
-0.06
-0.42
0.15
0.72
0.16
Reference
0.17
0.04
0.31
0.31
0.32
0.31
0.16
0.08
0.17
0.64
0.02
0.17
-0.57
0.10
0.18
-0.50
-1.68
-0.67
-0.42
Reference
0.35
-0.21
0.21
0.04
0.09
0.40
0.46
0.46
0.42
0.29
0.29
0.31
0.006
0.02
0.06
0.21
0.001
0.15
0.33
0.23
0.46
0.68
Results from multivariate linear regression analysis, all variables in the table being included in the model.
* Five missing total serum IgE.
the age of the mother, suggesting that age is positively
related to higher serum IgE levels in the children at the
age of 1 week. Maternal IgE level showed no association
with parity, but a borderline significant association with
neonatal IgE.
Role of essential fatty acid status
Maternal DHA status decreased with parity [regression
coefficient = -0.33, (SE = 0.12), P = 0.007]. Of the
other EFAs, only EPA also decreased with parity
[-0.08 (0.03), P = 0.02]. No effects of parity on DHA
or other EFAs were found in the neonates at 1 week of
age. When maternal DHA was included in the multiva-
riate models of Table 2, the regression coefficients of the
association between parity and maternal or neonatal IgE
hardly changed. This was also true when all other
maternal or neonatal EFAs were included. Maternal
DHA showed no statistically significant association with
maternal IgE on its own [regression coefficient = 0.15
(SE = 0.12), P = 0.18], or with neonatal IgE [0.09 (0.13),
P = 0.49].
In the explorative analyses of individual FAs and
neonatal IgE we found one influential outlier in the
regression analysis of 22:4n-6 in maternal blood
(Cook's distance 3.2). We omitted this outlier from
this analysis (Table 3). The explorative analyses found
a negative association between maternal LA levels and
neonatal IgE levels (P - 0.04) (Table 3). After correc-
tion for covariables, this association remained
(P = 0.03) and AA was positively associated with
neonatal serum IgE levels. Neonatal ALA levels were
negatively associated with neonatal IgE (P = 0.03),
while 18:4n-3 and DPA was positively associated
(P-values 0.02 and 0.03, respectively). After correction
for covariables, the association of ALA, 18:4n-3 and
DPA with neonatal IgE remained statistically signifi-
cant (/"-values 0.01, 0.049 and 0.04, respectively) and
EPA became negatively associated with neonatal IgE
levels (P = 0.047).
Discussion
The first aim of the present study was to evaluate the
association between parity and neonatal IgE levels. Our
results confirm Karmaus findings (6) that parity is
associated with lower IgE levels in neonatal serum. Other
determinants of neonatal IgE level were found to be
higher maternal IgE, higher maternal age and birth
outside the first 3 months of the year.
Our second hypothesis concerned the association
between parity and maternal and neonatal EFA status,
especially DHA. Other studies have shown that parity is
associated with lower maternal DHA status and also with
neonatal EFA status as measured in cord plasma and
umbilical vein and artery wall (16). Our data confirm that
maternal DHA decreases with increasing parity, but
neonatal DHA was unrelated to parity. There are several
potential explanations for our findings. First, there may
be mechanisms ensuring neonatal EFA status at the
expense of maternal EFA status. Secondly, the neonates
may be able to synthesize a sufficient amount of DHA
from its precursors soon after birth and normalize a
DHA deficit within 1 week. Current evidence is indecisive
for these explanations (22, 23). Nonetheless, although we
have found statistical relationships, causality cannot be
inferred from this type of study.
Our third hypothesis was that DHA and other EFAs
play a role in the relationship between parity and
neonatal IgE levels. No relationship was found between
maternal DHA and neonatal IgE levels. We assessed the
role of maternal DHA in the relationship between parity
and neonatal IgE by including maternal DHA in the
multivariate analysis. As the relationship between parity
and neonatal IgE did not change, we conclude that
964
Determinants of neonatal IgE level
Table 3. Neonatal IgE as natural logarithm (In) at 1 week of age, in relation to maternal phospholipid essential fatty acid (EFA) status at 34-36 weeks of gestation and
neonatal phospholipid EFA status at 1 week of age and covariables
Regression
Mean wt% coefficient, uncontrolled
(SD) for covariables (SE)
Maternal phospholipid,
18:2n-6, LA
18:3n-6, GLA
20:3n-6, DGLA
20:4n-6, AA
22:4n-6, adrenic acid*
22:5n-6, Osbond acid
18:3n-3, ALA
18:4n-3
20:5n-3, EPA
22:5n-3, DPA
22:6n-3, DHA
Neonatal phospholipid,
18:2n-6, LA
18:3n-6, GLA
20:3n-6, DGLA
20:4n-6, AA
22:4n-6, adrenic acid
22:5n-6, Osbond acid
18:3n-3, ALA
18:4n-3
20:5n-3, EPA
22:5n-3, DPA
22:6n-3, DHA
EFAs(n= 161)
21.63 (2.61)
0.04 (0.03)
3.53 (0.70)
8.22(1.49)
0.36 (0.07)
0.45(0.16)
0.25 (0.09)
0.12 (0.05)
0.34 (0.28)
0.55 (0.13)
3.79 (1.06)
EFAs (n = 178)
16.57 (2.41)
0.07 (0.05)
2.67 (0.72)
11.34(3.031
0.37 (0.12)
0.34(0.21)
0.11 (0.08)
0.06 (0.04)
0.32 (0.14)
0.32 (0.14)
3.87 (1.18)
-0.116(0.057)
4.143 (5.364)
-0.151 (0.213)
0.172 (0.099)
2.747 (2.024)
0.722 (0.937)
-1.523(1.683)
-2.597 (3.030)
0.959 (0.535)
1.413(1.179)
0.167 (0.140)
-0.020 (0.060)
-4.220 (3.148)
0.141 (0.202)
0.063 (0.048)
1.580(1.248)
-0.206(0.681)
-3.748 (1.758)
8.554 (3.612)
-1.227 (1.004)
2.243(1.052)
0.120 (0.124)
Standardized
coefficient.uncontrolled
for covariables P-value
-0.162
0.062
-0.057
0.137
0.108
0.062
-0.072
-0.068
0.142
0.096
0.095
-0.025
-0.101
0.053
0.100
0.096
-0.023
-0.160
0.177
-0.093
0.160
0.122
0.04
0.44
0.48
0.09
0.17
0.44
0.37
0.39
0.08
0.23
0.24
0.74
0.18
0.49
0.19
0.21
0.76
0.03
0.02
0.22
0.03
0.11
Regression coefficient,
controlled for
covariables (SE)
-0.129 (1.845)
4.236(5.311)
-0.166(0.211)
0.212 (0.097)
4.015 (1.978)
0.749 (0.956)
-1.237(1.702)
-3.986 (3.075)
0.539 (0.539)
1.088 (1.198)
0.084 (0.143)
0.009 (0.063)
-4.709(3.051)
-0.062 (0.251)
0.020 (0.063)
1.410(1.324)
-0.632 (0.653)
-4.747(2.110)
7.299 (3.674)
-1.942 (0.972)
2.469(1.206)
0.088 (0.126)
Standardized
coefficient, controlled
for covariables P-value
-0.180
0.063
-0.062
0.169
0.158
0.063
-0.059
-0.105
0.080
0.072
0.047
0.011
-0.113
-0.023
0.031
0.085
-0.071
-0.203
0.151
-0.145
0.175
0.053
0.02
0.42
0.43
0.03
0.04
0.43
0.47
0.20
0.32
0.37
0.56
0.89
0.13
0.80
0.75
0.29
0.33
0.03
0.049
0.047
0.04
0.49
Regression coefficients uncontrolled for covariables are between one particular EFA and neonatal In IgE. Regression coefficients controlled for covariables are between one
particular EFA and neonatal In IgE, controlled for parity, age of mother at time of delivery, IgE of mother, smoking during pregnancy, season of birth, atopic status of the father,
gender and type of feeding.
* One outlier excluded.
maternal DHA is not a confounding or intermediate
factor in this relationship. As this was also true when all
EFAs were included in the model together, it is not likely
that EFA status or any particular EFAs are confounding
or intermediate factors.
The above relationships were studied in a hypothesis-
driven approach. In a further analysis we explored
whether other perinatal EFAs might be related to
neonatal IgE levels. We found several associations that
can only be interpreted in the light of specific hypotheses.
There are currently two main hypotheses to explain the
relationship between EFAs and atopy. The first hypo-
thesis suggests that desaturation of LA and ALA into
their longer chain polyenes (LCPs) is impaired in atopic
subjects as a result of an impaired enzyme activity of
delta-6-desaturase (the delta-6-desaturase hypothesis)
(10, 24). This hypothesis is based observational studies
that found increased levels of LA and substantially lower
levels of its LCPs, such as A A, in blood (10-12), adipose
tissue (11) and breast milk (13) of adults with atopic
disease, when compared with healthy subjects. As regards
the n-6 EFAs, we did not confirm a higher LA level in
mother or neonate in relation to high neonatal IgE (in
fact, the reverse was found for maternal LA). Nor did we
find lower n-6 LCPs, and maternal AA was even higher in
relation to high neonatal IgE. As regards the n-3 EFAs,
no association was found between maternal EFAs and
neonatal IgE. The associations found for neonatal n-3
EFAs showed no pattern consistent with the delta-
6-desaturase hypothesis.
The second hypothesis is based on the time trends in
the prevalence of atopic diseases and the consumption of
FAs in developed countries (38). The increased con-
sumption of vegetable oils rich in LA and a simulta-
neously reduced consumption of fatty fish (rich in n-3
EFAs) has been accompanied by an increased prevalence
of atopic disease (25, 26). In atopic infants these
associations have been described (42, 43). It has there-
fore been hypothesized that the increased consumption
of LA and the consequent increase in the ratio between
n-6 and n-3 EFAs in the diet may have led to an increase
in atopic diseases (the n-6/n-3 EFA hypothesis). We
found no consistently higher n-6 and lower n-3 EFA
levels in relation with neonatal IgE. We conclude that
none of the relationships we found were in agreement
with any of the hypotheses on EFAs and atopy, and that
none of the changes showed a consistent pattern.
Nevertheless, the number of statistically significant
associations between neonatal n-3 EFAs and neonatal
IgE was higher than expected on the basis of chance and
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this topic therefore needs further research and perhaps a
different hypothesis.
The definition of atopy has been modified in the last
few years. In 2001, a revised nomenclature for allergy
was suggested by the European Academy of Allergology
and Clinical Immunology (EAACI) in a position
statement (40) The general accepted definition in the
preceding decades was described as follows: 'Atopy is a
personal or familial tendency to produce IgE antibodies
in response to low doses of antigens, usually proteins,
and to develop typical symptoms such as asthma,
rhinoconjunctivitis, or eczema/dermatitis.' However, in
this position statement it was acknowledged that atopy
is not always associated with increased IgE levels.
Therefore we have to be cautious with translating the
results to atopy.
Nonetheless, neonatal IgE is thought to be a determinant
of later atopy and the present results seem to contradict the
known relationship between perinatal EFAs and the later
development of atopy (14, 27, 28). However, most studies
used clinical atopic outcomes or composite outcomes
including clinical and laboratory data; the study in infants
that showed an association between cord blood EFAs and
later atopy did not find an association with later IgE either
(14). Further evidence that EFAs are not related to the IgE
component of atopy was found in the present study (results
presented elsewhere). We found that a relatively low
perinatal n-3 LCP status in the breastfed infants was
associated with greater severity of AD at age 1 year, but
not with total serum IgE at that age (van Gool
C.J.A.W., Thijs C., van Houwelingen A.C., Henquet
C.J.M., Dagnelie P.C., Schrander J., Menheere P.P.C.A.,
van den Brandt P.A., unpublished data). In a supplemen-
tation study with GLA we found that the increase in plasma
GLA during supplementation was associated with lower
severity of AD, but again not with total serum IgE (34). We
conclude that the effect of perinatal EFAs on the later
development of atopic disease must be independent of the
neonatal production of IgE and is not likely to be
influenced by parity.
Karmaus and Botezan provided several hypothetical
explanations for the possible in utero effects of parity on
total serum IgE levels in cord blood (29) and summarized
these explanations as the 'in utero programming disruption
hypothesis'. Changes in hormones, maternal immune
suppression to prevent rejection of the fetus, maternal
infections during pregnancy and lifestyle characteristics
such as smoking might all influence the environment of the
unborn child. One of two North-European studies found
blood IgE levels to be associated with parental smoking
during pregnancy (30), whereas the other found an
association with maternal caffeine and alcohol use (31).
A large German study showed no association between
birth season and cord blood IgE, and two North-
European studies were contradictory, one showing peaks
in late autumn (31) whereas the other showed the lowest
cord blood values in autumn (32). Another North-
European study found that exposure of the mother
during pregnancy to high levels of birch pollen resulted in
a tendency toward an increased risk of sensitization to the
same allergen in infants at risk of atopy (41). A Dutch
study showed an increased relative risk for children born
up to 3 months before the main pollen season, together
with an increased relative risk for cat, dog, egg white and
cow's milk allergens from November to January (35).
These results are consistent with our findings. We know
of no previous studies that have reported on the season-
ality of both maternal and neonatal IgE. Our finding of
higher maternal IgE levels in spring is consistent with
pollen allergy. To match this with our finding of lowest
neonatal IgE values in the first 3 months of the year, it is
important to recognize that the fetal ability to produce
IgE does not start before the second trimester (33). Our
finding of lowest neonatal IgE values in the first 3 months
of the year is consistent with second and third trimester
pregnancy outside the pollen season. Therefore, our
findings might suggest that pollen exposure in pregnant
women with a personal history of atopy confers intra-
uterine stimulation of fetal IgE production. In a review of
intrauterine influences on atopy, Jones concluded that
allergens but not IgE are transferred through the
placenta, and proposed that IgE is amniotically trans-
ferred and ingested by the fetus, and is later counterbal-
anced by transplacental IgG (33). If neonatal IgE
originated directly from the mother, it would show a
peak simultaneously with that of the mother, which it did
not in our study. Therefore, possible explanations include
fetal production of IgE stimulated by maternally trans-
ferred pollen allergens, transamniotic IgE transfer or
unknown maternal immunologic stimuli related to sea-
sonal allergy. However, because of multiple comparisons
in the analyses and because of inconsistent results in
previous studies we are very cautious in drawing definite
conclusions about seasonality. In our study maternal
total IgE seemed to decrease with parity (Table 1), but
this was not statistically significant in the regression
analysis (Table 2). In spite of this, it may still be a
confounder of the relationship between parity and
neonatal IgE. The multivariate regression analysis in
Table 2 controlled for this confounder.
The present study confirms the conclusions of earlier
studies: parity has a negative influence on the DHA status
in pregnant mothers and is also related to total serum IgE in
neonates at the age of 1 week. However, our results show
that the effect is independent of changes in EFA status.
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